MARKET

DSGN

DSGN

Design Therapeutics, Inc.
NASDAQ
4.030
+0.120
+3.07%
Closed 16:00 03/28 EDT
OPEN
3.900
PREV CLOSE
3.910
HIGH
4.090
LOW
3.820
VOLUME
220.94K
TURNOVER
0
52 WEEK HIGH
8.47
52 WEEK LOW
1.940
MARKET CAP
227.67M
P/E (TTM)
-3.3744
1D
5D
1M
3M
1Y
5Y
Wednesday 3/27 Insider Buying Report: SNPS, DSGN
NASDAQ · 1d ago
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Insider transactions for penny stocks indicate confidence or concern around the company's prospects. FTC Solar, Inc. And Ocuphire Pharma have recently had notable insider transactions. The Dow Jones index closed lower by over 150 points on Monday. FTC solar and Design Therapeutics are among the recent penny stocks with notable insider trades.
Benzinga · 2d ago
Weekly Report: what happened at DSGN last week (0318-0322)?
Weekly Report · 3d ago
Hold Rating Maintained for Design Therapeutics Amid Drug Reformulation and Program Updates
TipRanks · 03/21 06:18
Design Therapeutics, Inc.: Navigating Liquidity Risks Amidst Bank Failures
TipRanks · 03/21 06:00
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Dow Jones · 03/20 15:08
RBC Capital Reiterates Sector Perform on Design Therapeutics, Maintains $4 Price Target
Benzinga · 03/20 14:57
Design Therapeutics Price Target Maintained With a $5.00/Share by Wedbush
Dow Jones · 03/20 14:45
More
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

Webull offers Design Therapeutics Inc stock information, including NASDAQ: DSGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DSGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DSGN stock methods without spending real money on the virtual paper trading platform.